WO2002062824A3 - Method of treating amyloid ? precursor disorder - Google Patents

Method of treating amyloid ? precursor disorder Download PDF

Info

Publication number
WO2002062824A3
WO2002062824A3 PCT/US2002/003256 US0203256W WO02062824A3 WO 2002062824 A3 WO2002062824 A3 WO 2002062824A3 US 0203256 W US0203256 W US 0203256W WO 02062824 A3 WO02062824 A3 WO 02062824A3
Authority
WO
WIPO (PCT)
Prior art keywords
alzheimer
peptides
syndrome
disease
disorder
Prior art date
Application number
PCT/US2002/003256
Other languages
French (fr)
Other versions
WO2002062824A2 (en
Inventor
Lawrence Friedhoff
Joseph Buxbaum
Edward I Cullen
Original Assignee
Andrx Corp
Lawrence Friedhoff
Joseph Buxbaum
Edward I Cullen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Corp, Lawrence Friedhoff, Joseph Buxbaum, Edward I Cullen filed Critical Andrx Corp
Priority to EP02718903A priority Critical patent/EP1366061A4/en
Priority to CA002437480A priority patent/CA2437480A1/en
Publication of WO2002062824A2 publication Critical patent/WO2002062824A2/en
Publication of WO2002062824A3 publication Critical patent/WO2002062824A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods for the treatment and prevention of APP processing disorders such as Alzheimer's disease and Down's Syndrome which are based on the administration of an effective amount of a HMG-CoA reductase inhibitor to a mammal are disclosed. Additionally, methods for treatment and prevention of APP processing disorders such as Alzheimer's disease and Down's Syndrome which are based on the reduction of cellular cholesterol in a mammal are disclosed. These methods reduce the amount of AB peptides or decrease the formation of AB peptides or increase the clearance of AB peptides in a mammal suffering from Alzheimer's disease and Down's Syndrome. Figure (1) is a schematic which illustrates APP processing.
PCT/US2002/003256 2001-02-05 2002-02-05 Method of treating amyloid ? precursor disorder WO2002062824A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02718903A EP1366061A4 (en) 2001-02-05 2002-02-05 Method of treating amyloid beta precursor disorders
CA002437480A CA2437480A1 (en) 2001-02-05 2002-02-05 Method of treating amyloid .beta. precursor disorder

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26588601P 2001-02-05 2001-02-05
US60/265,886 2001-02-05

Publications (2)

Publication Number Publication Date
WO2002062824A2 WO2002062824A2 (en) 2002-08-15
WO2002062824A3 true WO2002062824A3 (en) 2002-11-21

Family

ID=23012272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/003256 WO2002062824A2 (en) 2001-02-05 2002-02-05 Method of treating amyloid ? precursor disorder

Country Status (3)

Country Link
EP (1) EP1366061A4 (en)
CA (1) CA2437480A1 (en)
WO (1) WO2002062824A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
ES2715496T3 (en) 2003-07-03 2019-06-04 Hdl Therapeutics Inc Methods and apparatus for creating derivatives of HDL particles with a reduced lipid content
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
JPWO2005063294A1 (en) * 2003-12-30 2007-12-13 興和株式会社 γ-secretase complex formation inhibitor
US20070161700A1 (en) 2004-12-28 2007-07-12 Kowa Company, Ltd. Inhibitor for the formation of y-secretase complex
TWI432195B (en) 2007-10-03 2014-04-01 Kowa Co Nerve cell death inhibiting agent
US10821133B2 (en) 2017-12-28 2020-11-03 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
CN118594035A (en) 2017-11-22 2024-09-06 Hdl治疗公司 System and method for priming a fluid circuit of a plasma processing system

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006470A1 (en) * 1993-08-30 1995-03-09 Merck & Co., Inc. Prevention and treatment of alzheimer's disease
JPH09178743A (en) * 1995-12-27 1997-07-11 Oriental Yeast Co Ltd Determinationof soluble app
WO1997048391A2 (en) * 1996-06-21 1997-12-24 Advanced Research And Technology Institute Methods and compositions comprising r-ibuprofen
DE19641180A1 (en) * 1996-09-24 1998-03-26 Schering Ag A method of displaying APP secretase modulation and its use as an agent for the treatment of Alzheimer's disease
US5976817A (en) * 1996-10-31 1999-11-02 Trustees Of Boston University Diagnostic method for detecting Alzheimer's disease in living patients
US6172277B1 (en) * 1997-10-28 2001-01-09 The Miriam Hospital Non-transgenic rodent model of alzheimer's disease
WO1999038498A1 (en) * 1998-01-28 1999-08-05 Warner-Lambert Company Method for treating alzheimer's disease
US6472421B1 (en) * 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
JP2002530122A (en) * 1998-11-25 2002-09-17 サイオス インコーポレイテッド Prevention and treatment of amyloid-related diseases
CA2389973A1 (en) * 1999-11-04 2001-05-10 Andrx Corporation Method of treating amyloid beta precursor disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1366061A4 *

Also Published As

Publication number Publication date
EP1366061A4 (en) 2006-04-26
CA2437480A1 (en) 2002-08-15
WO2002062824A2 (en) 2002-08-15
EP1366061A2 (en) 2003-12-03

Similar Documents

Publication Publication Date Title
WO2003016467A3 (en) Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
WO2003053219A3 (en) Methods for slowing senescence and treating and preventing diseases associated with senescence
WO2004071431A3 (en) Method and composition for treating neurodegenerative disorders
WO2002062824A3 (en) Method of treating amyloid ? precursor disorder
NO20012317D0 (en) Steps to Treat, Prevent and Reduce the Risk of Alzheimer's Disease Using an HMG COA Reductase Inhibitor
EP1997498A3 (en) Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
CA2391808A1 (en) Method for treatment of symptoms of central nervous system disorders
WO2002088101A3 (en) Inhibitors of bace
MXPA03010911A (en) Anti-ngf antibodies for the treatment of various disorders.
WO2002094228A8 (en) Prevention and treatment of allergies by helminthic regulation of ige
WO1999015159A3 (en) Methods for increasing apoe levels for the treatment of neurodegenerative disease
WO2005066337A3 (en) Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation
HK1131745A1 (en) Neurotoxic oligomers
IL167890A (en) Use of a chorionic gonadotropin in the preparation of a medicament for treating a chronic pelvic pain syndrome
WO2006055871A3 (en) Treatment for multiple sclerosis
WO2001032161A3 (en) Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders
WO2006034512A3 (en) Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes
WO2002094196A3 (en) Method of treatment for cancers associated with elevated
AU2002303817A1 (en) Compositions and methods for treating or preventing convulsions or seizures
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
WO2000012045A3 (en) Method for treating neurodegenerative disorders
WO2005123068A3 (en) Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
WO2001021647A3 (en) Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 527378

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002250013

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2437480

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002718903

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002718903

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002718903

Country of ref document: EP